---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-023762"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:39:35.578662+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics FY2024 net loss $10.7M; cash $10.0M; Abbott collaboration for Phase 3 tecarfarin trial

## Summary
- Net loss of $10.7M for FY2024 (vs $8.4M in 2023); G&A expenses nearly doubled to $6.8M.
- Cash and equivalents of $10.0M as of Dec 31, 2024, up from $8.4M year-end 2023; ~1.8M shares outstanding.
- Collaboration with Abbott (NYSE: ABT) to support pivotal Phase 3 TECH-LVAD trial of tecarfarin.
- FDA Type D meeting in Feb 2025 provided guidance for tecarfarin Phase 3 trial design; FDA requested full study synopsis.
- Appointed Dr. James J. Ferguson as CMO and Jeff Cole as COO; received ODD for tecarfarin in LVAD patients.

## SEC filing metadata
- accession: 0001213900-25-023762
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390025023762/0001213900-25-023762-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390025023762/ea023436601-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-023762
- JSON: https://secwatch.observer/filing/0001213900-25-023762.json
- Plain text: https://secwatch.observer/filing/0001213900-25-023762.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.